"Dopamine Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
| Descriptor ID |
D015259
|
| MeSH Number(s) |
D27.505.519.625.150 D27.505.696.577.150
|
| Concept/Terms |
Dopamine Agents- Dopamine Agents
- Agents, Dopamine
- Dopaminergic Agents
- Agents, Dopaminergic
- Dopaminergic Drugs
- Drugs, Dopaminergic
- Dopamine Drugs
- Drugs, Dopamine
Dopamine Effect- Dopamine Effect
- Effect, Dopamine
- Dopaminergic Effect
- Effect, Dopaminergic
- Dopaminergic Effects
- Effects, Dopaminergic
- Dopamine Effects
- Effects, Dopamine
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Agents".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Agents".
This graph shows the total number of publications written about "Dopamine Agents" by people in this website by year, and whether "Dopamine Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 3 | 2 | 5 |
| 1995 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 1 | 3 |
| 2019 | 0 | 2 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Agents" by people in Profiles.
-
Nimitvilai-Roberts S, Gioia D, Zamudio PA, Woodward JJ. Ethanol inhibition of lateral orbitofrontal cortex neuron excitability is mediated via dopamine D1/D5 receptor-induced release of astrocytic glycine. Neuropharmacology. 2021 07 01; 192:108600.
-
Giacometti LL, Barker JM. Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction. Brain Res. 2019 11 15; 1723:146390.
-
Siemsen BM, Reichel CM, Leong KC, Garcia-Keller C, Gipson CD, Spencer S, McFaddin JA, Hooker KN, Kalivas PW, Scofield MD. Effects of Methamphetamine Self-Administration and Extinction on Astrocyte Structure and Function in the Nucleus Accumbens Core. Neuroscience. 2019 05 15; 406:528-541.
-
Hedges DM, Obray JD, Yorgason JT, Jang EY, Weerasekara VK, Uys JD, Bellinger FP, Steffensen SC. Methamphetamine Induces Dopamine Release in the Nucleus Accumbens Through a Sigma Receptor-Mediated Pathway. Neuropsychopharmacology. 2018 05; 43(6):1405-1414.
-
Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, Revuelta GJ, Short EB. The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status. J Psychiatr Pract. 2017 05; 23(3):191-199.
-
Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang GS, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143.
-
Schacht JP. COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review. Pharmacogenomics J. 2016 10; 16(5):430-8.
-
Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 05; 31(5):709-14.
-
Amato D, Pum ME, Groos D, Lauber AC, Huston JP, Carey RJ, de Souza Silva MA, Müller CP. Neuropharmacology of light-induced locomotor activation. Neuropharmacology. 2015 Aug; 95:243-51.
-
Gwynette MF, Beck B, VandenBerg A, Stocking N. Under arrest: the use of amantadine for treatment-refractory mood lability and aggression in a patient with traumatic brain injury. J Clin Psychopharmacol. 2015 Feb; 35(1):102-4.